• +1-646-491-9876
    • +91-20-67278686

    Search

    Spinal Cord Injury Pipeline Review H1 2017

    Spinal Cord Injury Pipeline Review H1 2017

    • Report Code ID: RW0001799278
    • Category Pharmaceuticals
    • No. of Pages 174
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Spinal Cord Injury - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H1 2017, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

    Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 8, 1, 24 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 2 molecules, respectively.

    Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 4
    Spinal Cord Injury - Overview 5
    Spinal Cord Injury - Therapeutics Development 6
    Spinal Cord Injury - Therapeutics Assessment 17
    Spinal Cord Injury - Companies Involved in Therapeutics Development 27
    Spinal Cord Injury - Drug Profiles 42
    Spinal Cord Injury - Dormant Projects 151
    Spinal Cord Injury - Discontinued Products 155
    Spinal Cord Injury - Product Development Milestones 156
    Appendix 166

    List of Tables

    Number of Products under Development for Spinal Cord Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Spinal Cord Injury - Pipeline by AbbVie Inc, H1 2017
    Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H1 2017
    Spinal Cord Injury - Pipeline by Aevi Genomic Medicine Inc, H1 2017
    Spinal Cord Injury - Pipeline by Apollo Endosurgery Inc, H1 2017
    Spinal Cord Injury - Pipeline by Asterias Biotherapeutics Inc, H1 2017
    Spinal Cord Injury - Pipeline by Athersys Inc, H1 2017
    Spinal Cord Injury - Pipeline by BioArctic AB, H1 2017
    Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H1 2017
    Spinal Cord Injury - Pipeline by CSL Ltd, H1 2017
    Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
    Spinal Cord Injury - Pipeline by Histocell SL, H1 2017
    Spinal Cord Injury - Pipeline by Kadimastem Ltd, H1 2017
    Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H1 2017
    Spinal Cord Injury - Pipeline by MandalMed Inc, H1 2017
    Spinal Cord Injury - Pipeline by Mapreg SAS, H1 2017
    Spinal Cord Injury - Pipeline by Neuralstem Inc, H1 2017
    Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2017
    Spinal Cord Injury - Pipeline by New World Laboratories Inc, H1 2017
    Spinal Cord Injury - Pipeline by Omeros Corp, H1 2017
    Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H1 2017
    Spinal Cord Injury - Pipeline by PixarBio Corp, H1 2017
    Spinal Cord Injury - Pipeline by Protagenic Therapeutics Inc, H1 2017
    Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals Inc, H1 2017
    Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H1 2017
    Spinal Cord Injury - Pipeline by SanBio Inc, H1 2017
    Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2017
    Spinal Cord Injury - Pipeline by TissueGene Inc, H1 2017
    Spinal Cord Injury - Pipeline by Tumorend LLC, H1 2017
    Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
    Spinal Cord Injury - Pipeline by Vicore Pharma AB, H1 2017
    Spinal Cord Injury - Dormant Projects, H1 2017
    Spinal Cord Injury - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Spinal Cord Injury - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Spinal Cord Injury - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Spinal Cord Injury - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Spinal Cord Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AbbVie Inc
    Acorda Therapeutics Inc
    Aevi Genomic Medicine Inc
    Apollo Endosurgery Inc
    Asterias Biotherapeutics Inc
    Athersys Inc
    BioArctic AB
    BioAxone BioSciences Inc
    CSL Ltd
    Genervon Biopharmaceuticals LLC
    Histocell SL
    Kadimastem Ltd
    Kringle Pharma Inc
    MandalMed Inc
    Mapreg SAS
    Neuralstem Inc
    Neuronax SAS
    New World Laboratories Inc
    Omeros Corp
    Pharmicell Co Ltd
    PixarBio Corp
    Protagenic Therapeutics Inc
    Remedy Pharmaceuticals Inc
    RespireRx Pharmaceuticals Inc
    SanBio Inc
    Stemedica Cell Technologies Inc
    TissueGene Inc
    Tumorend LLC
    Vertex Pharmaceuticals Inc
    Vicore Pharma AB

    Request for Sample

    Report Url http://www.reportsweb.com//spinal-cord-injury-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//spinal-cord-injury-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//spinal-cord-injury-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments